CATEGORY: HEART & CIRCULATION
Blood pressure that runs a little high. Weight that’s crept up. A kidney value your lab report flags. Four of the country’s biggest medical societies now treat those as pieces of one condition, and their first joint guideline for it reports that nearly 90% of US adults carry at least one of its risk factors.1 The condition is cardiovascular-kidney-metabolic syndrome, or CKM: the tangle in which excess weight, high blood sugar, failing kidneys and heart disease feed one another. The syndrome was named in a 2023 advisory. This document is the first full playbook telling clinicians what to do about it. The American Heart Association and the American College of Cardiology published the guideline this June in Circulation and JACC, and the American Diabetes Association, its Obesity Association and the American Society of Nephrology all stand behind it.1
Staged From 0 to 4, the Way Cancer Is
The guideline’s centerpiece borrows an idea most people know from cancer care: staging. Stage 0 means no risk factors at all. Stage 1 is extra weight or prediabetes on its own. Stage 2 adds metabolic risk factors such as high blood pressure, unhealthy cholesterol or type 2 diabetes, or chronic kidney disease. Stage 3 is the silent phase, where heart or vessel disease shows up on tests without causing symptoms, or where kidney disease and risk scores run high enough to count as its equivalent. Stage 4 is diagnosed cardiovascular disease, anything from a heart attack to heart failure to stroke, and it splits in two depending on whether the kidneys have failed. The ladder exists for timing, not labeling. Caught at the early stages, the authors write, the syndrome can be slowed or even pushed backward.1 Few conditions cast a wider net: roughly 40% of US adults have obesity, which by itself places them on the ladder.1 So do about one in five US children and teens.1
A Risk Calculator That Counts the Kidneys
To place people on stages, clinicians are pointed to the PREVENT equations, risk calculators the heart association built so that kidney function and metabolic health count toward a person’s predicted risk. Older heart-risk tools largely ignored both. The equations estimate the 10-year chance of cardiovascular disease for adults ages 30 to 79, plus a 30-year outlook for younger adults, and a 10-year risk of 20% or more lands a person at stage 3 on its own. A 10-year risk of 7.5% or more is where the document says preventive drug therapy starts entering the conversation. Testing reaches past the standard labs, too: in the right patients, the guideline calls for checks for early heart failure, fatty liver disease and sleep apnea, three conditions that ride along with the syndrome and often go unlooked-for. It also asks clinicians to screen for things no blood panel catches: food insecurity, unstable housing and financial strain. It even asks each care team to name a single point person, so a patient with three conditions isn’t left refereeing three specialists.
Where the Newest Drugs Fit
For the first time in an AHA and ACC guideline, GLP-1-based medicines, which mimic a gut hormone to lower blood sugar and weight, are recommended for selected people with obesity or type 2 diabetes plus other cardiovascular risk factors, specifically to cut the risk of cardiac events.1 SGLT2 inhibitors, pills that make the kidneys pass extra sugar out in the urine, are named first-line when kidney disease comes with diabetes or with protein leaking into the urine. Weight-loss surgery stays among the options. None of it displaces the basics the document leads with: activity, nutrition, weight, blood pressure, blood sugar and cholesterol, managed together rather than one per appointment. That’s the real argument of the whole guideline. These conditions share machinery, so the care should share a plan.
Key Takeaways
- The first-ever guideline for cardiovascular-kidney-metabolic (CKM) syndrome treats heart, kidney and metabolic disease as one connected condition, staged from 0 to 4 like cancer.
- Nearly 90% of US adults have at least one CKM risk factor, and the guideline holds that the early stages can be slowed or reversed.
- Risk gets scored with PREVENT equations that include kidney and metabolic health, and clinicians are told to screen for food insecurity, unstable housing and financial strain alongside lab values.
- GLP-1 medicines earned their first recommendation in these guidelines for lowering cardiac-event risk in selected people, and SGLT2 inhibitors are first-line for diabetic kidney disease.
References
- Ndumele CE, Rodriguez F, Dixon DL, et al. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;154(4):e50–e158. link